Targeting CDK4 and CDK6 in cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
General Earth and Planetary Sciences,General Environmental Science
Link
https://www.nature.com/articles/s41568-022-00456-3.pdf
Reference263 articles.
1. Asghar, U., Witkiewicz, A. K., Turner, N. C. & Knudsen, E. S. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat. Rev. Drug Discov. 14, 130–146 (2015).
2. Losiewicz, M. D., Carlson, B. A., Kaur, G., Sausville, E. A. & Worland, P. J. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem. Biophys. Res. Commun. 201, 589–595 (1994).
3. Sanchez-Martinez, C., Lallena, M. J., Sanfeliciano, S. G. & de Dios, A. Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: recent advances (2015-2019). Bioorg. Med. Chem. Lett. 29, 126637 (2019).
4. Malumbres, M. Cyclin-dependent kinases. Genome Biol. 15, 122 (2014).
5. Malumbres, M. et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 118, 493–504 (2004). Using Cdk4 and Cdk6 double-knockout mice, this study establishes that mammalian cells can proliferate in the absence of both CDK4 and CDK6, demonstrating a plasticity of cyclin–CDK networks that has implications for CDK4/6 inhibitor resistance.
Cited by 217 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Pirfenidone inhibits CCL2-mediated Treg chemotaxis induced by palbociclib and fulvestrant in HR+/HER2− breast cancer;International Immunopharmacology;2024-12
2. Questionnaire survey and analysis of drug clinical research implementation capabilities of breast cancer treatment departments in Chinese hospitals;The Breast;2024-10
3. A Graph Curvature-Based Pipeline for Discovering Immune Checkpoint Response Biomarkers;2024-09-08
4. Posttranslational modifications of E2F family members in the physiological state and in cancer: Roles, mechanisms and therapeutic targets;Biomedicine & Pharmacotherapy;2024-09
5. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment;Drug Resistance Updates;2024-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3